MichaelJohnLillestolMD

Internal Medicine • Fargo, ND

Internist at IMA Healthcare

Join to view full profile

Dr. Lillestol is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lillestol's full profile

Already have an account?

Office
4450 31st Ave S
Fargo, ND 58104
Phone+1 701-280-2033

Fax+1 701-232-5578

Summary

Dr. Michael Lillestol is an internist in Fargo, ND and is affiliated with multiple hospitals in the area, including Sanford Medical Center, Essentia Health, and Cobalt rehab hospital. He received his medical degree from University of Minnesota Medical School and has been in practice 43 years. He specializes in hospital medicine/hospitalist.

Education & Training

Abbott-Northwestern HospitalResidency, Internal Medicine, 1974 - 1977
University of Minnesota Medical SchoolClass of 1974

Certifications & Licensure

MN State Medical License 1971 - 2025
ND State Medical License 1971 - 2025
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
Completed
Phase 3
Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) Start of enrollment: 2013 Aug 01
Completed
Phase 3
12-Week Study of Plecanatide for CIC (The CIC3 Study) Start of enrollment: 2013 Nov 01
Completed
Phase 3
A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes Start of enrollment: 2014 Apr 01
Completed
Phase 2
A Study of LY2623091 in Participants With High Blood Pressure Start of enrollment: 2014 Aug 01
Completed
Phase 2
A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol Start of enrollment: 2014 Oct 01
Terminated
Phase 3
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus Start of enrollment: 2017 May 24
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Dia...
Elena A Christofides, Andrzej Stankiewicz, Douglas Denham, Diego Bellido, Edward Franek
Endocrine Practice. 2024-09-01
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 di...
Elena A Christofides, Orlando Puente, Paul Norwood, Douglas Denham, Hiralal Maheshwari
Diabetes, Obesity & Metabolism. 2024-06-01
516 citations
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Dirk J. Blom, Tomas Hala, Michael A. Bolognese, Michael J. Lillestol, Phillip D. Toth
The New England Journal of Medicine. 2014-05-07

Press Mentions

Lillestol Research for Future GenerationsJune 10th, 2019